Previous 10 | Next 10 |
FSD Pharma (HUGE +52% on licensing deal for veterinary drugs in dogs and cats.Zhongchao (ZCMD +49% after contract renewal with China Association of Health Promotion and Education and GlaxoSmithKline.Immatics N.V. (IMTX +24% on announcing a clinical data update fr...
Gainers: SunLink Health Systems (SSY) +219%.Can-Fite BioPharma (CANF) +53%.Savara (SVRA) +37%.Fintech Acquisition (FTCVU) +31%.New Fortress Energy (NFE) +27%.Lizhi (LIZI) +26%.Enzo Biochem (ENZ) +25%.iSun (ISUN) +23%.Anchiano Therapeutics (ANCN) +21%.OptimizeRx (OPRX) +21%...
Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...
Jefferies analyst Michael Yee predicts Biogen (BIIB) shares to rally up to $400 – 500 range if the company’s experimental Alzheimer’s disease medicine gets the regulatory approval in the U.S.Despite the doubts over its commercial prospects, the analyst expects Aducanumab ...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in full by the underwriters of their o...
Savara (SVRA) has gained ~11.5% in the premarket after Oppenheimer initiated its coverage with an outperform rating and a price target of $4.00 per share implying ~154.8% upside to the previous close.The firm notes that the company’s development efforts have primarily focused...
Intec Pharma Ltd (NTEC) +142% on announcing merger agreement with Decoy Biosystems.Check-Cap Ltd. (CHEK) +113% after receiving FDA IDE approval for pivotal study of C-Scan®.Acer Therapeutics (ACER) +67%.Shaw Communications (SJR) +55% as Rogers to acquire the company in C$2...
Eli Lilly (LLY) has lost ~4.8% in the pre-market after the company’s full Phase 2 data for donanemab in early stage of Alzheimer's disease failed to impress the Wall Street analysts.Biogen (BIIB), the developer of much anticipated Alzheimer’s therapy, aducanumab has ad...
Savara (SVRA) announces the pricing of an underwritten public offering of 45.7M shares at $1.45/share for gross proceeds of $113M.Has also granted the underwriters a 30-day option to purchase up to 11.69M additional shares. The offering is expected to close on March 15, 2021.Intends...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara ...
News, Short Squeeze, Breakout and More Instantly...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...
2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...